Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Completed · Phase 1
Conditions studied: Renal Cell Carcinoma, Urinary Bladder Neoplasms
In brief
Primary objective: To assess the early signals for anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma. Secondary objectives: (1) To evaluate the overall safety profile of pembrolizumab in combination with vorinostat; (2) To assess the safety and tolerability of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma in order to select the recommended Phase 2 Dose (RP2D)
Key facts
- Study ID
- NCT02619253
- Run by
- Nabil Adra
- People needed
- 52
- Starts
- 2016-02-23
- Expected to finish
- 2023-03-28
- Last updated by the study team
- 2024-11-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- Indiana University Hospital — Indianapolis, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.